Literature DB >> 8669890

Evidence that the amino acid region 124-203 of glycoprotein G from the respiratory syncytial virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection.

C Simard1, F Nadon, C Séguin, M Trudel.   

Abstract

The first 230 residues of the 298-amino acid glycoprotein G of respiratory syncytial virus (RSV) are sufficient to confer complete resistance to challenge with live RSV, whereas the first 180 residues completely failed (Olmsted et al. (1989) J. Virol. 63, 411-420). The characterization of a protective epitope corresponding to the amino acid region 174-187 of the G protein (Trudel et al. (1991) Virology 185, 749-757) suggests that interruption of this region in the 180 residue truncated polypeptide may be responsible for its inability to confer protection and consequently that the 174-187 region may play a major role in the protection effected by the protein G. To support these hypotheses, we examined the ability of the amino acid region 124-203 of glycoprotein G to confer protection. The corresponding peptide was expressed as a non-fusion protein in a recombinant vaccinia virus designated VG27. Immunization of BALB/c mice with this recombinant efficiently induced the production of antibodies capable of recognizing both the parental glycoprotein G and peptide 174-187. Furthermore, upon challenge with RSV, a significant decrease of infectious particles was found in the lungs of mice immunized with VG27 as compared with non-immunized mice. Our results suggest that the 124-203 amino acid region of the RSV G protein constitutes a major part of the domain involved in protection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8669890     DOI: 10.1016/0166-3542(95)00053-4

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  11 in total

1.  Determination of the disulfide bond arrangement of human respiratory syncytial virus attachment (G) protein by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  J J Gorman; B L Ferguson; D Speelman; J Mills
Journal:  Protein Sci       Date:  1997-06       Impact factor: 6.725

2.  Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.

Authors:  H Plotnicky-Gilquin; L Goetsch; T Huss; T Champion; A Beck; J F Haeuw; T N Nguyen; J Y Bonnefoy; N Corvaïa; U F Power
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

3.  Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.

Authors:  Lori W McGinnes; Kathryn A Gravel; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Madelyn R Schmidt; Trudy G Morrison
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

4.  Evolution of bovine respiratory syncytial virus.

Authors:  J F Valarcher; F Schelcher; H Bourhy
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism.

Authors:  T R Johnson; B S Graham
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

6.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

7.  Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein.

Authors:  Kalina T Zlateva; Philippe Lemey; Anne-Mieke Vandamme; Marc Van Ranst
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Genetic variability among complete human respiratory syncytial virus subgroup A genomes: bridging molecular evolutionary dynamics and epidemiology.

Authors:  Lydia Tan; Philippe Lemey; Lieselot Houspie; Marco C Viveen; Nicolaas J G Jansen; Anton M van Loon; Emmanuel Wiertz; Grada M van Bleek; Darren P Martin; Frank E Coenjaerts
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

9.  Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia.

Authors:  T E Sparer; S Matthews; T Hussell; A J Rae; B Garcia-Barreno; J A Melero; P J Openshaw
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

10.  Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge.

Authors:  T R Johnson; J E Johnson; S R Roberts; G W Wertz; R A Parker; B S Graham
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.